The Belgian vertical farm rewriting how the world sources rare medicinal plants.
BOTALYS, Ath, Belgium.
The wordmark set against the wild - the exact conditions its indoor farm is built to recreate, then improve upon.
In a 2,000-square-metre building in the small Belgian town of Ath, ginseng that normally needs five years in a field grows in a matter of months. There is no soil, no sun, and no pesticides. There is, instead, a very deliberate deception.
BOTALYS is a botanical-ingredients company, but that description undersells the strangeness of what it actually does. It grows rare medicinal plants indoors, at pharmaceutical purity, using a method it calls Biomimetic Indoor Farming. The idea is simple to state and hard to execute: recreate the ideal - and often harsh - conditions a plant would face in the wild, then control every variable of that environment. Fake seasons. Simulated stress. Precisely tuned light, water and nutrients. A plant under the right kind of pressure produces more of the active compounds that make it valuable in the first place, and BOTALYS engineers that pressure on purpose.
The company was founded in 2011 by Pierre-Antoine Mariage, originally under the name Green2Chem, and spent roughly six years in research before it had a method worth commercializing. In 2019 it launched its first product: HRG80, a hydroponic Korean red ginseng powder marketed as carrying the highest concentration of rare ginsenosides available on the market. Ginsenosides are the compounds prized for ginseng's effects on mental stamina and stress resilience, and the rare fractions are exactly the ones traditional field cultivation produces least of.
"BOTALYS is dedicated to producing ultra-pure premium botanicals for health."
— The company's own framing of its missionThat is the through-line for everything the company sells. Where the natural-ingredients industry has long wrestled with heavy metals, pesticide residues and batches that never quite match, BOTALYS removed the biggest source of that variability - the open field - from the equation entirely. Its pitch to customers is not merely "natural." It is traceable, contaminant-free, and consistent from one batch to the next. In an industry flooded with the word natural, the differentiator turned out to be proof.
The technology combines vertical farming and hydroponics inside a sterile, controlled space. The goal is not comfort for the plant - it is calibrated hardship.
Recreate a rare plant's native biotope - light, climate, seasons.
Simulate hardship so the plant builds up active compounds.
Compress a multi-year cycle into months, soil-free.
Purify and batch-match to a consistent compound profile.
Approximate cultivation time. Faster cycles also yield higher concentrations of rare ginsenosides.
BOTALYS sells purified, standardized botanical ingredients - not finished consumer products - to companies that formulate supplements, cosmetics and pharmaceuticals.
Hydroponic red ginseng (Panax ginseng) powder concentrated in rare ginsenosides. Marketed with the highest concentration of rare ginsenosides on the market and used in supplements for mental stamina and cognitive resilience. HRG80 stands for Hydroponic Red Ginseng, ~80% rare ginsenosides.
Indoor-grown Rhodiola rosea for stress and energy applications - the first major expansion of the portfolio beyond ginseng.
Salvia miltiorrhiza, a rare medicinal plant being developed for health and pharmaceutical uses.
Botanical actives co-developed for skincare and cosmeceutical formulations, including work with cosmetics majors.
BOTALYS operates strictly B2B. Its ingredients travel into the products of supplement brands, cosmetic formulators and pharmaceutical companies rather than onto a shelf under its own name. Known customers and partners for the HRG80 ginseng include Terry Naturally in the United States, Nutrisan in Belgium and Therascience - the kind of brands whose credibility rests on ingredient quality.
The bigger signal is who has chosen to partner with the company. In 2023 it signed a co-development and distribution deal with Seppic, a subsidiary of Air Liquide Healthcare. In 2024 it worked alongside L'Oreal and the AI-bioactives firm Brightseed. By 2025 its name appeared in the orbit of consumer-health multinational Haleon. When companies that size come to a 27-person grower, it is usually because the grower solves a purity or supply problem they cannot solve themselves.
Most vertical-farming attention goes to lettuce and leafy greens - high volume, low value. BOTALYS pointed the same class of technology at rare medicinal plants worth far more per gram, where the economics of controlled-environment growing actually make sense.
Removing open-field cultivation strips out heavy metals, pesticide residues and seasonal inconsistency at the source.
Deliberate, controlled stress pushes plants to concentrate the rare fractions - like specific ginsenosides - that buyers value most.
Standardization turns an unpredictable natural input into a reliable, specable ingredient - a feature customers pay a premium for.
Growing in Belgium, indoors and year-round, sidesteps the geopolitical and climate risk baked into traditional botanical sourcing.
The competitive set is split: on one side, traditional Korean and Chinese field-grown ginseng and classic extract houses; on the other, emerging plant-cell and hairy-root biotech producers. BOTALYS sits between them - real whole-plant material, but grown with the control of a lab.
Pierre-Antoine Mariage launches the venture that becomes BOTALYS and begins R&D into indoor cultivation of rare plants.
The proprietary cultivation method matures after roughly six years of research.
Backing from VIVES and Wallonia mechanisms funds a jump to industrial-scale production.
The first commercial ingredient - a hydroponic Korean red ginseng rich in rare ginsenosides.
Recognition for innovation as the company wins new supplement-brand customers.
A ~6.6M€ round funds industrialization and international expansion.
Co-development and distribution deal opens cosmetics and health markets.
New rhodiola ingredient launches alongside collaborations with L'Oreal and Brightseed.
The company extends into cosmetic active ingredients and appears within the Haleon healthcare network.
Raised with VIVES fund, new private shareholders and the SWAN - Seal of Excellence Wallonia mechanism, funding the move to industrial production in Ath.
Led by ALIAD, Air Liquide's venture capital fund, with participation reported from VIVES and Belgian regional investor SRIW. Total funding to date is reported around 7.9M USD.
Headquartered in Ath, Wallonia, with a reported presence in Austin, Texas. Revenue and current valuation are not publicly disclosed.
It grows rare medicinal plants - starting with Korean ginseng - inside an indoor vertical farm and sells the resulting ultra-pure, standardized botanical ingredients to supplement, cosmetic and pharmaceutical companies.
HRG80 is BOTALYS's flagship hydroponic red ginseng powder, marketed as having the highest concentration of rare ginsenosides available on the market, used for mental stamina and cognitive resilience.
Its Biomimetic Indoor Farming method recreates and tightly controls the plant's ideal - and deliberately harsh - growing conditions, cutting ginseng's typical 4-5 year field cycle down to months while raising active-compound content.
In Ath, in Belgium's Walloon region, where it operates one of Europe's largest vertical farms dedicated to medicinal plants, with a reported presence in Austin, Texas.
Investors include VIVES, SRIW and Air Liquide's venture fund ALIAD, which led its ~6.6M euro Series B in 2022. Partners and customers include Seppic, L'Oreal, Brightseed, Haleon, Terry Naturally and Nutrisan.
Video and demo content lives on the company's official channel.